• Pooja Santosh Devkate
• Ashwini More

Obesity is an emerging disease worldwide. Changing lifestyle habits, particularly increased consumption of high-calorie foods and reduced physical activity, lead to an energy imbalance that leads to weight gain. More than one-third of U.S. adults suffer from obesity, which negatively impacts numerous medical comorbidities, including diabetes mellitus and cardiovascular disease.The severity of the condition necessitates more extreme measures, like as medication, medical devices, and bariatric surgery, even in the face of drastic lifestyle modifications. Cost, accessibility, and perioperative and postoperative problems are the most frequent drawbacks of bariatric surgery. Naltrexone and bupropion are centrally acting drugs that have demonstrated potential efficacy in treating obesity both individually and in combination. Long-term success is unusual in weight loss attempts.Weight gain, recurrent binge eating, conversions and reoperations ranging from 1.6% to 3.5%, and a 7.3% perioperative complication rate are all linked to bariatric surgery.

Naltrexone, Bupropion, Contrave, Pharmacotherapy.

"Naltrexone and Bupropion for obesity: an investigational combination pharmacotherapy for weight loss", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 6, page no.b515-b530, June-2024, Available :http://www.jetir.org/papers/JETIR2406162.pdf

"Naltrexone and Bupropion for obesity: an investigational combination pharmacotherapy for weight loss", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 6, page no. ppb515-b530, June-2024, Available at : http://www.jetir.org/papers/JETIR2406162.pdf